AP NEWS

CivaTech Oncology, Inc. Offers New Technology to Fight Lung Cancer

August 8, 2018

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug 8, 2018--Physicians are now able to successfully implant a new bio-absorbable, internal radiation treatment known as CivaSheet® to treat a patient with recurrent lung cancer. Approximately 234,000 patients per year in the U.S. are diagnosed with lung cancer, and of those, approximately 30% to 55% of patients with non-small cell lung cancer develop recurrence.

In March 2018, a team of experts at Memorial Sloan Kettering Cancer Center (MSK) completed the procedure. A post-operative dosimetry study showed the radiation was effectively delivered in a simple surgical procedure that can effectively provide an ideal dose directly to the surgical margin in a one-time therapy. No complications or radiation related side effects have been reported. MSK physicians performed a second lung implant using a CivaSheet® last week.

Designed and manufactured by Civatech Oncology, CivaSheet® is a flexible, implantable intra-operative radiation therapy device (brachytherapy), which emits unidirectional radiation by integrating gold shielding into the CivaSheet. The unidirectional property makes the device active on one side to provide a homogenous radiation dose. This is entirely unique to CivaSheet®. Physicians can now safely deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissue. Radiation is delivered as the isotope naturally decays over the course of several weeks – no repeated hospital trips are needed for radiation therapy. No follow-up procedure is necessary to remove the device.

The implantation of CivaSheet® occurs following a tumor resection from the lung. In a 15-minute operating room procedure, the surgical team cuts the CivaSheet® to fit and affixes it to the area they want to treat. CivaSheet® delivers a highly-targeted radiation dose to the immediate area where residual cancer cells potentially remain.

CivaSheet has broad FDA clearance to include lung cancer and many other malignancies. A NIH/NCI Fast-Track grant award, value of up to $2.3M, is in place to fund a multi-institutional research protocol to evaluate the safety and efficacy of the CivaSheet when used to treat lung cancer.

About CivaTech Oncology:

CivaTech Oncology’s products bring meaningful improvements to provide targeted radiation therapy. For more information, please visit  www.civatechoncology.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180808005062/en/

CONTACT: CivaTech Oncology Inc.®

Randy Harrison, 919-314-5515

National Sales Manager

rharrison@civatechoncology.com

KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY RADIOLOGY OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE MANAGED CARE

SOURCE: CivaTech Oncology

Copyright Business Wire 2018.

PUB: 08/08/2018 08:00 AM/DISC: 08/08/2018 08:01 AM

http://www.businesswire.com/news/home/20180808005062/en

AP RADIO
Update hourly